Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Proc Natl Acad Sci U S A Retrieve available abstracts of 56 articles: HTML format

Single Articles

March 2024
1. HAN X, Wang D, Yang L, Wang N, et al
   Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer.
   Proc Natl Acad Sci U S A. 2024;121:e2319429121.
   PubMed     Abstract available
   
   
   February 2024
2. JANSEN RA, Mainardi S, Dias MH, Bosma A, et al
   Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.
   Proc Natl Acad Sci U S A. 2024;121:e2319492121.
   PubMed     Abstract available
   
   
   January 2024
3. CHEN NY, Lin CW, Lai TY, Wu CY, et al
   Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.
   Proc Natl Acad Sci U S A. 2024;121:e2313397121.
   PubMed     Abstract available
   
   
   
4. WU XN, Li JY, He Q, Li BQ, et al
   Targeting the PHF8/YY1 axis suppresses cancer cell growth through modulation of ROS.
   Proc Natl Acad Sci U S A. 2024;121:e2219352120.
   PubMed     Abstract available
   
   
   December 2023
5. LEE H, Jung JH, Ko HM, Park H, et al
   RNA-binding motif protein 10 inactivates c-Myc by partnering with ribosomal proteins uL18 and uL5.
   Proc Natl Acad Sci U S A. 2023;120:e2308292120.
   PubMed     Abstract available
   
   
   October 2023
6. CHUNG YH, Ortega-Rivera OA, Volckaert BA, Jung E, et al
   Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis.
   Proc Natl Acad Sci U S A. 2023;120:e2221859120.
   PubMed     Abstract available
   
   
   
7. IM SJ, Obeng RC, Nasti TH, McManus D, et al
   Characteristics and anatomic location of PD-1(+)TCF1(+) stem-like CD8 T cells in chronic viral infection and cancer.
   Proc Natl Acad Sci U S A. 2023;120:e2221985120.
   PubMed     Abstract available
   
   
   
8. GINN L, Maltas J, Baker MJ, Chaturvedi A, et al
   A TIAM1-TRIM28 complex mediates epigenetic silencing of protocadherins to promote migration of lung cancer cells.
   Proc Natl Acad Sci U S A. 2023;120:e2300489120.
   PubMed     Abstract available
   
   
   September 2023
9. SUAREZ JS, Novelli F, Goto K, Ehara M, et al
   HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma.
   Proc Natl Acad Sci U S A. 2023;120:e2307999120.
   PubMed     Abstract available
   
   
   
10. CHEN Y, Shi J, Wang X, Zhou L, et al
    An antioxidant feedforward cycle coordinated by linker histone variant H1.2 and NRF2 that drives nonsmall cell lung cancer progression.
    Proc Natl Acad Sci U S A. 2023;120:e2306288120.
    PubMed     Abstract available
    
    
    
11. LIN X, Chen Y, Lin L, Yin K, et al
    mitoSplitter: A mitochondrial variants-based method for efficient demultiplexing of pooled single-cell RNA-seq.
    Proc Natl Acad Sci U S A. 2023;120:e2307722120.
    PubMed     Abstract available
    
    
    
12. YOUSEFI M, Andrejka L, Szamecz M, Winslow MM, et al
    Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
    Proc Natl Acad Sci U S A. 2023;120:e2303224120.
    PubMed     Abstract available
    
    
    July 2023
13. XIAO GY, Tan X, Rodriguez BL, Gibbons DL, et al
    EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2220276120.
    PubMed     Abstract available
    
    
    February 2023
14. JANSSEN K, Claes F, Van de Velde D, Wehbi VL, et al
    Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein.
    Proc Natl Acad Sci U S A. 2023;120:e2214921120.
    PubMed     Abstract available
    
    
    
15. WU L, Kohno M, Murakami J, Zia A, et al
    Defining and targeting tumor-associated macrophages in malignant mesothelioma.
    Proc Natl Acad Sci U S A. 2023;120:e2210836120.
    PubMed     Abstract available
    
    
    
16. CHUANG TP, Lai WY, Gabre JL, Lind DE, et al
    ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression.
    Proc Natl Acad Sci U S A. 2023;120:e2216479120.
    PubMed     Abstract available
    
    
    
17. BASSEY-ARCHIBONG BI, Rajendra Chokshi C, Aghaei N, Kieliszek AM, et al
    An HLA-G/SPAG9/STAT3 axis promotes brain metastases.
    Proc Natl Acad Sci U S A. 2023;120:e2205247120.
    PubMed     Abstract available
    
    
    
18. ZHANG Z, Lu YX, Liu F, Sang L, et al
    lncRNA BREA2 promotes metastasis by disrupting the WWP2-mediated ubiquitination of Notch1.
    Proc Natl Acad Sci U S A. 2023;120:e2206694120.
    PubMed     Abstract available
    
    
    
19. LI H, Liu Y, Xiao Y, Wilson CN, et al
    CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors.
    Proc Natl Acad Sci U S A. 2023;120:e2212072120.
    PubMed     Abstract available
    
    
    January 2023
20. BUGIDE S, Edwards YJK, Gupta R, Green MR, et al
    CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2218118120.
    PubMed     Abstract available
    
    
    
21. BONONI A, Wang Q, Zolondick AA, Bai F, et al
    BAP1 is a novel regulator of HIF-1alpha.
    Proc Natl Acad Sci U S A. 2023;120:e2217840120.
    PubMed     Abstract available
    
    
    November 2022
22. LIU W, Tai CH, Liu X, Pastan I, et al
    Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures.
    Proc Natl Acad Sci U S A. 2022;119:e2214928119.
    PubMed     Abstract available
    
    
    September 2022
23. ZHOU C, Wang D, Li J, Wang Q, et al
    TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets TGFB2 and SOX2.
    Proc Natl Acad Sci U S A. 2022;119:e2117988119.
    PubMed     Abstract available
    
    
    August 2022
24. WANG Z, Zhu J, Liu Y, Wang Z, et al
    Tumor-polarized GPX3(+) AT2 lung epithelial cells promote premetastatic niche formation.
    Proc Natl Acad Sci U S A. 2022;119:e2201899119.
    PubMed     Abstract available
    
    
    July 2022
25. BROWN BP, Zhang YK, Kim S, Finneran P, et al
    Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2206588119.
    PubMed     Abstract available
    
    
    
26. WANG D, Wang Q, Wang Y, Chen P, et al
    Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides.
    Proc Natl Acad Sci U S A. 2022;119:e2113180119.
    PubMed     Abstract available
    
    
    
27. MA L, Yang F, Wu X, Mao C, et al
    Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity.
    Proc Natl Acad Sci U S A. 2022;119:e2117054119.
    PubMed     Abstract available
    
    
    May 2022
28. 
    Retraction for Motiwala et al., Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2200127119.
    PubMed    
    
    
    
29. SCHOLZ A, DeFalco J, Leung Y, Aydin IT, et al
    Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101.
    Proc Natl Acad Sci U S A. 2022;119:e2123483119.
    PubMed     Abstract available
    
    
    
30. FENG S, Callow MG, Fortin JP, Khan Z, et al
    A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors.
    Proc Natl Acad Sci U S A. 2022;119:e2120512119.
    PubMed     Abstract available
    
    
    April 2022
31. AHMED M, Kaur N, Cheng Q, Shanabrough M, et al
    A hypothalamic pathway for Augmentor alpha-controlled body weight regulation.
    Proc Natl Acad Sci U S A. 2022;119:e2200476119.
    PubMed     Abstract available
    
    
    February 2022
32. XU Q, Wang C, Zhou JX, Xu ZM, et al
    Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available
    
    
    
33. SONG NY, Li X, Ma B, Willette-Brown J, et al
    IKKalpha-deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available
    
    
    December 2021
34. SCHULT TA, Lauer MJ, Berker Y, Cardoso MR, et al
    Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
35. ZHAO X, Hu J, Li Y, Guo M, et al
    Volumetric compression develops noise-driven single-cell heterogeneity.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    November 2021
36. CHEON H, Holvey-Bates EG, McGrail DJ, Stark GR, et al
    PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
37. DE S, Holvey-Bates EG, Mahen K, Willard B, et al
    The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    September 2021
38. LLABATA P, Torres-Diz M, Gomez A, Tomas-Daza L, et al
    MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
39. 
    Correction for Jeon et al., A set of NF-kappaB-regulated microRNAs induces acquired TRAIL resistance in Lung cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    
    
    
    August 2021
40. MUELLER HS, Fowler CE, Dalin S, Moiso E, et al
    Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    July 2021
41. SALMON M, Paniagua G, Lechuga CG, Fernandez-Garcia F, et al
    KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
42. LIU Z, Wang F, Liu X, Sang Y, et al
    Cell membrane-camouflaged liposomes for tumor cell-selective glycans engineering and imaging in vivo.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    June 2021
43. ETXEBERRIA I, Bolanos E, Teijeira A, Garasa S, et al
    Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
44. SHI L, Tan X, Liu X, Yu J, et al
    Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
45. SANCHEZ-RIVERA FJ, Ryan J, Soto-Feliciano YM, Clare Beytagh M, et al
    Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    May 2021
46. PRADHAN AK, Maji S, Bhoopathi P, Talukdar S, et al
    Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1beta.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
47. DING Y, Liu Y, Lee DK, Tong Z, et al
    Cell lineage tracing links ERalpha loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
48. TIEN JC, Chugh S, Goodrum AE, Cheng Y, et al
    AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
49. WANG R, Godet I, Yang Y, Salman S, et al
    Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
50. TILSTON-LUNEL A, Mazzilli S, Kingston NM, Szymaniak AD, et al
    Aberrant epithelial polarity cues drive the development of precancerous airway lesions.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    April 2021
51. WAN PK, Tong KC, Lok CN, Zhang C, et al
    Platinum(II) N-heterocyclic carbene complexes arrest metastatic tumor growth.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    March 2021
52. YANG L, Yan X, Chen J, Zhan Q, et al
    Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
53. BROWNLIE D, Scharenberg M, Mold JE, Hard J, et al
    Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    February 2021
54. JIMENEZ-SANCHEZ J, Bosque JJ, Jimenez Londono GA, Molina-Garcia D, et al
    Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    January 2021
55. CHIBAYA L, Karim B, Zhang H, Jones SN, et al
    Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    
    
56. XIAO Y, Lin FT, Lin WC
    ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.